+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

World Paclitaxel Injection Market - Opportunities and Forecasts, 2017 - 2023

  • PDF Icon

    Report

  • September 2019
  • Region: Global
  • Allied Market Research
  • ID: 3773558
Paclitaxel belongs to the group of medications known as antineoplastics and is used in the treatment of cancers. It works by inhibiting the growth of cancer cells and is used in the treatment of various cancers such as breast cancer, ovarian cancer, non small cell lung cancer, etc. According to the WHO, cancer was the leading cause of death worldwide, accounting for the death of 8.2 million people in 2012. The major drivers for this market are the rising incidence of cancer globally and the improved efficacy of paclitaxel injections. However, adverse drug reactions associated with the drug as well as the emergence of targeted treatment, personalized medicine and novel anti-cancer drugs would be a challenge to the growth of this market. The opportunities for this market are its potential to be used for treatment for various types of cancers.

Paclitaxel Injection Market by use in treatment of various cancers

Paclitaxel Injection is used in the treatment of Breast cancer, Ovarian cancer, Non small cell lung cancer, AIDS related Kaposi's sarcoma, Cervical Cancer, Esophageal cancer, Prostate cancer , Stomach cancer, Testicular cancer, Lung cancer, Pancreatic cancer, and Others. According to the WHO, stomach cancer accounted for 723,000 deaths and breast cancer accounted for 521,000 deaths respectively in the year 2012 alone. Paclitaxel is used for the treatment of both these cancers and the rising incidences of cancer would result in increased use of this drug for treatment.

Paclitaxel Injection Market by Geography

Paclitaxel Injection Market is segmented geographically into North America, Europe, Asia Pacific and RoW. Currently the market is dominated by North America due to the high incidence of Cancer patients in this region. However, Europe and Asia Pacific are emerging markets due to rising incidences of cancer.

Competitive analysis

The companies in this market are Abraxis Bio Science Inc., Celgene, Abbott Laboratories, Fresenius Kabi Oncology Ltd, Onco therapies Ltd, Novasep, Sagent Pharmaceuticals and others. The European Commission approved ABRAXANE to be taken in combination with Gentamicin for the treatment of metastatic pancreatic cancer in January 2014. ABRAXANE was developed by Celgene International Sàrl, a subsidiary of Celgene Corporation.

High Level Analysis

Porter’s five force model analyzes the bargaining power of the suppliers and buyers as well as the threat of new entrants. The threat of substitutes in this market is high, with extensive research and development being carried out in anti-cancer drugs. SWOT analysis helps in making strategic decisions for development and expansion. The key drivers, restraints and opportunities are analyzed to help in better understanding the growth of this market.

Key Benefits

Market segmentation by use of the product would help in identification of future applications
Porter’s five force model helps in making strategic business decisions for business development
In-depth geographic Analysis would aid in identifying regions where demand for this product would increase
In-depth analysis of drivers and opportunities would help in understanding the future potential of this market

Key Deliverables

Paclitaxel Injection Market is segmented by use in treatment of cancer and geography.

Paclitaxel Injection Market by use in treatment of various cancers

Breast cancer
Ovarian cancer
Non small cell lung cancer
AIDS related Kaposi's sarcoma
Cervical Cancer
Esophageal cancer
Prostate cancer
Stomach cancer
Testicular cancer
Lung cancer
Pancreatic cancer
Others.

Paclitaxel Injection Market by Geography

North America
Europe
Asia Pacific
RoW

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...